Francesco Massari

18.6k total citations · 7 hit papers
479 papers, 9.9k citations indexed

About

Francesco Massari is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Francesco Massari has authored 479 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 259 papers in Pulmonary and Respiratory Medicine, 181 papers in Oncology and 143 papers in Surgery. Recurrent topics in Francesco Massari's work include Renal cell carcinoma treatment (127 papers), Cancer Immunotherapy and Biomarkers (113 papers) and Prostate Cancer Treatment and Research (77 papers). Francesco Massari is often cited by papers focused on Renal cell carcinoma treatment (127 papers), Cancer Immunotherapy and Biomarkers (113 papers) and Prostate Cancer Treatment and Research (77 papers). Francesco Massari collaborates with scholars based in Italy, United States and Spain. Francesco Massari's co-authors include Matteo Santoni, Rodolfo Montironi, Veronica Mollica, Alessandro Rizzo, Liang Cheng, Antonio López-Beltrán, Marina Scarpelli, Alessia Cimadamore, Giampaolo Tortora and Matteo Rosellini and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Francesco Massari

450 papers receiving 9.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony

2002 528 citations Massimo Iacoviello, Francesco Massari et al. profile →
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

2021 187 citations Antonio López-Beltrán, Alessia Cimadamore et al. Cancers profile →
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

2022 138 citations Matteo Rosellini, Andrea Marchetti et al. profile →
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study

2022 123 citations Matteo Santoni, Alessandro Rizzo et al. Critical Reviews in Oncology/Hematology profile →
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

2023 117 citations Matteo Santoni, Alessandro Rizzo et al. profile →
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study

2023 115 citations Veronica Mollica, Alessandro Rizzo et al. profile →
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study

2023 107 citations Alessandro Rizzo, Veronica Mollica et al. profile →

Peers

Countries citing papers authored by Francesco Massari

Since Specialization

Citations

This map shows the geographic impact of Francesco Massari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Massari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Massari more than expected).

Fields of papers citing papers by Francesco Massari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Massari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Massari. The network helps show where Francesco Massari may publish in the future.

Co-authorship network of co-authors of Francesco Massari

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Massari. A scholar is included among the top collaborators of Francesco Massari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Massari. Francesco Massari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Congestion and systemic inflammation in acute heart failure: correlations and prognostic role 2025 ·Frontiers in Cardiovascular Medicine ·Pietro Scicchitano, (unknown), Massimo Iacoviello, Stefano Albani, Gabriella Ricci, (unknown), (unknown), Pasquale Caldarola, Marco Matteo Ciccone, Francesco Massari	0
2	Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study 2025 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Costantino Ricci, Francesca Ambrosi, (unknown), (unknown), (unknown), Francesco Vasuri, (unknown), (unknown), Francesco Massari, Veronica Mollica, Andrea Marchetti, (unknown), Maurizio Colecchia, (unknown), João Lobo, Michelangelo Fiorentino	2
3	Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis 2024 ·Critical Reviews in Oncology/Hematology ·Fernando Sabino Marques Monteiro, Andrey Soares, Veronica Mollica, Caio A. Leite, (unknown), Alessandro Rizzo, María T. Bourlon, (unknown), Matteo Santoni, Shilpa Gupta, Francesco Massari	7
4	Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis 2024 ·Scientific Reports ·Elsa Vitale, (unknown), (unknown), Deniz Can Güven, Raffaella Massafra, Veronica Mollica, Fernando Sabino Marques Monteiro, Matteo Santoni, Francesco Massari	8
5	FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal‐type 2023 ·Histopathology ·Costantino Ricci, Francesca Ambrosi, (unknown), Francesca Giunchi, (unknown), (unknown), Francesco Massari, Veronica Mollica, Valentina Tateo, (unknown), Maurizio Colecchia, Andrés Acosta, Michelangelo Fiorentino	10
6	Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 2023 ·International Journal of Molecular Sciences ·Thais Maloberti, Antonio De Leo, (unknown), (unknown), Elisa Gruppioni, Annalisa Altimari, (unknown), Francesca Giunchi, Francesco Vasuri, Michelangelo Fiorentino, Veronica Mollica, Simona Ferrari, Sara Miccoli, Michela Visani, Daniela Turchetti, Francesco Massari, Giovanni Tallini, Dario de Biase	3
7	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 2022 ·Cancers ·Andrea Marchetti, Matteo Rosellini, (unknown), Elisa Tassinari, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Andrea Farolfi, Rodolfo Montironi, Stefano Fanti, Francesco Massari	11
8	Genomics and Immunomics in the Treatment of Urothelial Carcinoma 2022 ·Current Oncology ·Veronica Mollica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K. Menta, Jacob J. Adashek	9
9	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT 2021 ·International Journal of Molecular Sciences ·Veronica Mollica, Andrea Marchetti, Matteo Rosellini, (unknown), Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Rodolfo Montironi, Francesco Massari	18
10	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art 2021 ·Cancers ·Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, (unknown), Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, Francesco Massari	37
11	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16) 2021 ·Oncology ·Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, Francesco Massari, Alessandra Bearz, Lucia Fratino, Michèle Milella, Maria Bassanelli, Paola Ermacora, Davide Bimbatti, Elena Verzoni, Mimma Rizzo, Camillo Porta	2
12	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views 2021 ·Cancers ·Gaetano Aurilio, Matteo Santoni, Francesco Massari, Alessia Cimadamore, Alessandro Rizzo, Veronica Mollica, Elena Verri, Nicola Battelli, Rodolfo Montironi	13
13	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation 2021 ·Cancers ·Alessia Cimadamore, Roberta Mazzucchelli, Antonio López-Beltrán, Francesco Massari, Matteo Santoni, Marina Scarpelli, Liang Cheng, Rodolfo Montironi	8
14	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 2020 ·Clinical Genitourinary Cancer ·Matteo Santoni, Francesco Piva, Camillo Porta, Sergio Bracarda, Daniel Y.C. Heng, Marc Matrana, Enrique Grande, Veronica Mollica, Gaetano Aurilio, Mimma Rizzo, Matteo Giulietti, Rodolfo Montironi, Francesco Massari	20
15	Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers 2020 ·Diagnostics ·Francesca Giunchi, Francesco Massari, Annalisa Altimari, Elisa Gruppioni, Elisabetta Nobili, Michelangelo Fiorentino, Andrea Ardizzoni	5
16	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 2020 ·Cells ·Gaetano Aurilio, Alessia Cimadamore, Matteo Santoni, Franco Nolè, Marina Scarpelli, Francesco Massari, Antonio López-Beltrán, Liang Cheng, Rodolfo Montironi	8
17	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis 2020 ·Diagnostics ·Francesca Giunchi, (unknown), Elisa Gruppioni, Annalisa Altimari, Elisa Capizzi, Francesco Massari, Riccardo Schiavina, Matteo Brunelli, Guido Martignoni, Michelangelo Fiorentino	3
18	Comparison and optimization of genetic tools used for the identification of ancient fish remains recovered from archaeological excavations and museum collections in the Mediterranean region 2019 ·International Journal of Osteoarchaeology ·(unknown), Alessia Cariani, Elisabetta Cilli, Francesco Massari, (unknown), Arturo Morales Muñiz, Vedat Onar, (unknown), Darío Bernal Casasola, Tom Moens, Fausto Tinti	5
19	Long‐term clinical impact of PSA surge in castration‐resistant prostate cancer patients treated with abiraterone 2017 ·The Prostate ·Vincenza Conteduca, Orazio Caffo, Cristian Lolli, Michele Aieta, Emanuela Scarpi, Emanuela Bianchi, Francesca Maines, Giuseppe Schepisi, Samanta Salvi, Francesco Massari, Francesco Carrozza, Antonello Veccia, Vincenzo Emanuele Chiurì, (unknown), Gaetano Facchini, Ugo De Giorgi	7
20	Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·Pietro Ghedini, Irene Bossert, Lucia Zanoni, Francesco Ceci, Tiziano Graziani, Paolo Castellucci, Valentina Ambrosini, Francesco Massari, Elisabetta Nobili, Barbara Melotti, Alessandra Musto, Stefania Zoboli, Lidija Antunovic, Margarita Kirienko, Arturo Chiti, Cristina Mosconi, Andrea Ardizzoni, Rita Golfieri, Stefano Fanti, Cristina Nanni	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact